Could Denosumab Support Bone Integrity in Sickle Cell Disease
Journal Title: Journal of Hematology & Thrombosis - Year 2015, Vol 1, Issue 2
Abstract
Sickle cell anaemia is a congenital disease characterized by painful vaso-occlusive crises. It is associated with vitamin D deficiency, osteoporosis and recurrent attacks of micro-infarctions lead to bone osteonecrosis. The most common sites of osteonecrosis in sickle cell disease are the femoral and humeral heads which could lead to severe pain and extensive physical disability. Denosumab is a new human monoclonal antibody product; it is a receptor activator of nuclear factor kappa B ligand RANKL. That decreases osteoclastic bone restoration. It is Food and Drug Administration FDA approved for osteoporosis for women with high risk of fracture; and it is also being used for the treatment and prevention of bone loss in patients undergoing hormone ablation therapy for breast and prostate cancer. Denosumab is not restricted for sickle cell disease patients within its approved indications. It has less nephrotoxicity effect than the bisphosphonates which is a big advantage for sickle cell patients. It also used as an adjuvant agent to reduce metastatic bone pain in solid tumors. The extension of Denosumab use for sickle cell patients’ osteoporosis and osteonecrosis deserve a randomized multi central trail aiming to improve bone integrity and possible reduction of the devastating pain in sickle cell disease patients.
Authors and Affiliations
Hassan Al-Jafar
Keywords
Related Articles
- EP ID EP246518
- DOI 10.13188/2380-6842.1000009
- Views 146
- Downloads 0
Large Granular Lymphocytic Leukemia and Cocaine Abuse in A Patient With Chronic Neutropenia - Are They Co-Existing or Causally Related?
Chronic neutropenia is a hematological condition that could cause significant morbidity due to recurrent infections. Various benign and malignant disorders manifest with chronic neutropenia and a meticulous evaluation is...
The Evaluation of Cardiac Disorders and Systemic Hypertension in JAK2V617F Positive Patients at a Multicenter Institution
In this retrospective study; we evaluate cardiac disorders and systemic hypertension in JAK2 V617F positive patients. We identified 1000 patients in our hospital system that had been evaluated for JAK2 V617F mutation. Am...
Provisional Study of Kuwait Adult Hematology Reference Range
Introduction: Hematology reference range provides valuable information for the correct interpretation of results for proper diagnosis and treatment. Previous studies have shown that hematology reference range may vary in...
Recombinant Human Soluble Thrombomodulin is Effective for Severe Childhood EBV-HLH
Hemophagocytic lymphohistiocytosis (HLH) is a fatal disease, presenting with T cell-induced dysregulated cytokine production, systemic inflammation, and frequently intractable coagulopathy. We have administered recombina...
Differences in Circulating Endothelial Progenitor Cells among Childhood Cancer Survivors Treated with and without Radiation
Radiation during childhood cancer treatment increases the propensity to atherosclerotic cardiovascular disease among adult survivors of childhood cancer. This is thought to be mediated through the damage to the underlyin...